MGC Pharmaceuticals (ASX:MXC) share price climbs on study approval

The Israeli Ministry of Health has approved a dosing study of a drug candidate. Here are the details

| More on:
A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is shooting higher and is currently up around 2% at 4.9 cents. Earlier in the day it was up to 5.1 cents, a gain of around 6% on the previous closing price.

MGC shares have been in the green all day after the biopharmaceuticals and phytomedicine company announced a key update regarding its drug candidate CimetrA.

Here are the details.

What did MGC Pharmaceuticals announce?

MGC said the Israeli Ministry of Health had approved a dosing study of CimetrA, indicated in the potential treatment of Covid-19. Today's announcement appears to have impressed investors, pushing the MGC Pharmaceuticals share price higher.

For reference, CimetrA is formulated from naturally derived anti-inflammatories found in the plants Curcumin and Boswellia (also known as Indian frankincense).

A dosing study is a necessary step in a drug's approval process. It is used to determine the most effective amount of active ingredient required to achieve a desired response, without causing any adverse side effects.

The aim is to identify a label's "therapeutic dose" alongside a wider safety profile, in preparation for registration and sale to the public.

As such, MGC's latest study will "further examine the anti-inflammatory and immune-modulatory effects of CimetrA".

It will recruit 240 patients across a number of jurisdictions, including Israel, South Africa, the US, and Russia. After which, results will be submitted to the health authorities of each country.

Interpretation of the results will then be used to determine the "most effective dosage of CimetrA for treating symptoms of Covid-19". This includes a rare but serious complication known as a 'cytokine storm'.

Cytokines are markers in the body that are critical in regulating the immune system. Covid-19 can cause them to be released in overwhelming abundance — a cytokine storm — which is detrimental to the body's tissues.

Previous studies MGC has undertaken support CimetrA's use as an immune system modulator that is effective in preventing and treating cytokine storms.

This appears significant, as cytokine storms are believed to be the main cause of death in Covid-19 patients.

What is management saying?

Speaking on the announcement possibly driving the MGC Pharmaceuticals share price, co-founder and managing director Roby Zomer said:

This latest dosage study is the latest step as we move closer to being in a position to apply for marketing authorisation for CimetrA™ in territories across the globe.

We believe that CimetrA will prove to be a vitally important drug in the treatment of COVID-19 going forward, and look forward to sharing the results of the study in due course, along with further steps towards providing COVID-19 patients and governments across the world a cost-effective treatment to fast-track patient recovery and minimise the massive cost burden of long-term hospitalisation.

MGC Pharmaceuticals share price snapshot

The MGC Pharmaceuticals share price has been an outsized winner this year to date, having climbed almost 100%.

It has also gained 122% over the past 12 months. That's well ahead of the benchmark S&P/ASX 200 index (ASX: XJO)'s return of around 25% in that time.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Lab worker puts hands in the air and dances around.
Healthcare Shares

Guess which ASX 300 stock just jumped 12% on FDA approval

Investors are piling into the ASX 300 stock following big US news.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Healthcare Shares

Broker says Telix shares could surge 80% higher after selloff

Let's see what Bell Potter has to say about this beaten down healthcare share.

Read more »

A doctor looks unsure.
Dividend Investing

Down 11% in a year, are CSL shares now a good income buy?

CSL shares have faced headwinds from potential US pharmaceutical tariffs.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

What does Macquarie think Resmed shares are worth after its result?

Resmed's share price is gaining momentum.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward representing the ASX tech share sell-off today
Share Fallers

Why did the Telix share price just plunge 18%?

ASX investors are punishing Telix shares today. But why?

Read more »

A man pulls a shocked expression with mouth wide open as he holds up his laptop.
Healthcare Shares

ResMed share price is on watch for all-time highs

Powered by rising margins, global growth, and confidence from management, this sleep tech stock is turning heads again.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Why this $7 billion ASX 200 healthcare share is now trading at a discount

With revenue surging, a leading expert believes the ASX 200 healthcare stock has been oversold.

Read more »

woman happy at dividends she will recieve
Healthcare Shares

What does JP Morgan think Resmed shares are worth after reviewing its FY25 result?

Resmed shares reached a new all-time high last Friday.

Read more »